# A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

> **NCT00002318** · PHASE3 · UNKNOWN · sponsor: **Sequus Pharmaceuticals** · enrollment: 225 (—)

## Conditions studied

- Sarcoma, Kaposi
- HIV Infections

## Interventions

- **DRUG:** Doxorubicin hydrochloride (liposomal)
- **DRUG:** Bleomycin sulfate
- **DRUG:** Vincristine sulfate
- **DRUG:** Doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00002318
- **Lead sponsor:** Sequus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 225 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002318, "A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*